2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.042 Kelsey Pan NACLC23 Abstract

PP01.042 Kelsey Pan NACLC23 Abstract

Pdf Summary

A study conducted at the University of Texas MD Anderson Cancer Center evaluated the incidence, clinical characteristics, prognosis, and management of lung cancer patients with EGFR germline mutations. The researchers analyzed data from the Lung Cancer Moon Shot GEMINI database and identified 22 patients with confirmed germline EGFR mutations. The majority of these patients (95.5%) had an EGFR T790M mutation and an EGFR L858R somatic mutation. The study found that the patients were predominantly female, non-smokers, Caucasian, and diagnosed at stage IV. Additionally, 22.7% of patients had brain metastasis at diagnosis, and a distinct radiographic pattern of small multifocal ground-glass pulmonary nodules was observed in the majority of patients. <br /><br />Among the patients with advanced-stage lung adenocarcinoma, 66.7% were treated with first-line osimertinib and had a median progression-free survival (PFS) of 16.9 months. Other patients were treated with afatinib or chemotherapy as first-line therapy. In the group of patients with advanced-stage NSCLC treated with osimertinib, the median PFS was 20.4 months and the median overall survival (OS) was 82.0 months.<br /><br />The study concludes that EGFR germline mutations in non-small cell lung cancer (NSCLC) are more common in Caucasian females and are associated with a radiographic pattern of small multifocal ground-glass pulmonary nodules. Treatment with osimertinib in advanced germline EGFR-mutated NSCLC showed similar PFS compared to somatic T790M EGFR-mutated NSCLC. The findings from this study contribute to the understanding of EGFR germline mutations in lung adenocarcinoma and may inform treatment decisions for patients with these mutations.

Keywords

lung cancer

EGFR germline mutations

clinical characteristics

prognosis

management

ground-glass pulmonary nodules

osimertinib

progression-free survival

NSCLC

treatment decisions